Bio-Thera Solutions, Ltd. (SHA:688177)

China flag China · Delayed Price · Currency is CNY
20.69
-0.51 (-2.41%)
At close: Apr 29, 2026
-3.86%
Market Cap 8.57B
Revenue (ttm) 980.25M
Net Income (ttm) -390.44M
Shares Out 414.08M
EPS (ttm) -0.94
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,375,512
Average Volume 3,383,718
Open 21.23
Previous Close 21.20
Day's Range 20.67 - 21.27
52-Week Range 20.15 - 36.32
Beta 0.53
RSI 36.89
Earnings Date Apr 28, 2026

About Bio-Thera Solutions

Bio-Thera Solutions, Ltd., a biopharmaceutical company, researches and develops novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs in China and internationally. It offers QLETLI for the treatment of ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn’s disease, and uveitis; POBEVCY to treat patients with metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, cervical cancer, and epitheli... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 1,266
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688177
Full Company Profile

Financial Performance

In 2025, Bio-Thera Solutions's revenue was 935.22 million, an increase of 25.84% compared to the previous year's 743.17 million. Losses were -331.94 million, -34.95% less than in 2024.

Financial Statements

News

There is no news available yet.